Surgical Treatment of Aortic Valve Disease With Moderate Functional Mitral Regurgitation

Fuwai Yunnan Cardiovascular Hospital0 sites154 target enrollmentOctober 2022

ConditionsFunctional Mitral Regurgitation

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Functional Mitral Regurgitation
Sponsor: Fuwai Yunnan Cardiovascular Hospital
Enrollment: 154
Primary Endpoint: left ventricular global longitudinal strain
Status: Not yet recruiting
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Debates exist on the treatment of moderate functional mitral regurgitation (FMR) in patients undergoing aortic valve replacement (AVR) for aortic valve disease. This study aims to evaluate the left ventricular function, which was evaluated through global longitudinal strain, after isolated AVR and AVR + mitral valve repair (MVr) in this group of patients.

Registry

clinicaltrials.gov

Start Date

October 2022

End Date

December 2023

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Fuwai Yunnan Cardiovascular Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients who received AVR (with or without concomitant MVr) from two center (Fuwai Yunnan Cardiovascular Hospital and Fuwai Hospital, Chinese Academy of Medical Sciences).
•Age more than 18 years.

Exclusion Criteria

•Those with a history of rheumatic valvular disease or infective endocarditis.
•Primary mitral valve lesions.
•Patients receiving mitral valve replacement.
•Patient who refuse to participate in this study, or cannot complete 6-month follow-up after surgery.
•Age \< 18 years.